Irritable Bowel Syndrome
Lotronex Tablets now available for women with severe diarrhea-predominant IBS
Published in Women's Health Weekly, January 2nd, 2003
Lotronex (alosetron hydrochloride) Tablets will now be available under restricted conditions of use, which include a narrower indication for specific use in female patients with severe diarrhea-predominant irritable bowel syndrome (IBS), an extensive risk management program requiring participation of physicians, patients, and pharmacists, and several additional safety and efficacy studies.
"We're entering a new era for pharmaceuticals in the U.S.," said Peter Traber, MD, senior vice president and chief medical officer at GlaxoSmithKline. "The industry, the Food and Drug Administration (FDA), the medical profession, and patients are all recognizing our joint...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Infertility
Vascular growth factor a prerequisite for normal uterine implantation - Menopause
Study raises questions about HRT in diabetic women - Assisted Reproduction
Risk for hepatitis C virus in semen presents need for laboratory caution - Breast Cancer
Elderly women undertreated? - Contraception
Intranasal immunization with sperm-specific antigen has vaccine potential - Epidemiology
Women account for half of HIV cases for the first time - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
